|
审核状态: Project audit state: |
通过审核 Successful |
|
注册号: Registration number: |
ChiCTR2500103896 |
|
最近更新日期: Date of Last Refreshed on: |
2025-06-06 17:06:18 |
|
注册时间: Date of Registration: |
2025-06-06 00:00:00 |
|
注册号状态: |
预注册 |
|
Registration Status: |
Prospective registration |
|
注册题目: |
高强度训练联合碳酸氢钠补充对健康人群机体衰老的影响 |
|
Public title: |
Effect of high-intensity training combined with sodium bicarbonate supplementation on aging in healthy people |
|
注册题目简写: |
|
|
English Acronym: |
|
|
研究课题的正式科学名称: |
高强度训练联合碳酸氢钠补充对健康人群机体衰老的影响 |
|
Scientific title: |
Effect of high-intensity training combined with sodium bicarbonate supplementation on aging in healthy people |
|
研究课题代号(代码): Study subject ID: |
|
|
在二级注册机构或其它机构的注册号: The registration number of the Partner Registry or other register: |
|
申请注册联系人: |
刘雅 |
研究负责人: |
谢亘青 |
|
Applicant: |
Ya Liu |
Study leader: |
Genqing Xie |
|
申请注册联系人电话: Applicant telephone: |
+86 155 8081 5436 |
研究负责人电话:
Study leader's |
+86 181 6360 2595 |
|
申请注册联系人传真 : Applicant Fax: |
研究负责人传真: Study leader's fax: |
||
|
申请注册联系人电子邮件: Applicant E-mail: |
359223031@qq.com |
研究负责人电子邮件: Study leader's E-mail: |
genqingxie@qq.com |
|
申请单位网址(自愿提供): Applicant website(voluntary supply): |
研究负责人网址(自愿提供): Study leader's website(voluntary supply): |
||
|
申请注册联系人通讯地址: |
湖南省长沙市开福区湘雅路87号 |
研究负责人通讯地址: |
湖南省湘潭市岳塘区书院路100号 |
|
Applicant address: |
No.87, Xiangya Road, Kaifu District, Changsha City, Hunan Province |
Study leader's address: |
No.100, Shuyuan Road, Yuetang District, Xiangtan City, Hunan Province |
|
申请注册联系人邮政编码: Applicant postcode: |
研究负责人邮政编码: Study leader's postcode: |
||
|
申请人所在单位: |
中南大学湘雅医院 |
||
|
Applicant's institution: |
Xiangya hospital of central south university |
||
|
研究负责人所在单位: |
湘潭市第一人民医院 |
||
|
Affiliation of the Leader: |
The first people's hospital of Xiangtan hospital |
||
|
是否获伦理委员会批准: |
是 |
||
|
Approved by ethic committee: |
Yes |
||
|
伦理委员会批件文号: Approved No. of ethic committee: |
2025052005 |
伦理委员会批件附件: Approved file of Ethical Committee: |
查看附件View |
|
批准本研究的伦理委员会名称: |
湘潭市第一人民医院伦理委员会 |
||
|
Name of the ethic committee: |
Ethics Committee of Xiangtan First People's Hospital |
||
|
伦理委员会批准日期: Date of approved by ethic committee: |
2025-05-20 00:00:00 | ||
|
伦理委员会联系人: |
杨杰 |
||
|
Contact Name of the ethic committee: |
Jie Yang |
||
|
伦理委员会联系地址: |
湖南省湘潭市岳塘区书院路100号 |
||
|
Contact Address of the ethic committee: |
No. 100, Shuyuan Road, Yuetang District, Xiangtan City, Hunan Province |
||
|
伦理委员会联系人电话: Contact phone of the ethic committee: |
+86 732 5866 9195 |
伦理委员会联系人邮箱: Contact email of the ethic committee: |
|
|
研究实施负责(组长)单位: |
湘潭市第一人民医院 |
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Primary sponsor: |
Xiangtan First People's Hospital |
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
研究实施负责(组长)单位地址: |
湖南省湘潭市岳塘区书院路100号 |
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Primary sponsor's address: |
No. 100, Shuyuan Road, Yuetang District, Xiangtan City, Hunan Province |
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
试验主办单位(项目批准或申办者): Secondary sponsor: |
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
经费或物资来源: |
国家级课题 |
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Source(s) of funding: |
National Funding |
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
研究疾病: |
衰老 |
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Target disease: |
Aging |
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
研究疾病代码: |
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Target disease code: |
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
研究类型: |
干预性研究 |
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Study type: |
Interventional study |
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
研究所处阶段: |
其它 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Study phase: |
N/A |
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
研究设计: |
随机平行对照 |
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Study design: |
Parallel |
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
研究目的: |
主要目的 本研究旨在通过随机平行对照实验设计,系统评估高强度训练联合口服碳酸氢钠干预对健康受试者衰老生理的影响。 次要目的 评估高强度训练对健康人群衰老状态的独立影响。 探讨碳酸氢钠补充对高强度训练后衰老影响的协同作用 |
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Objectives of Study: |
main purpose This study aims to systematically evaluate the effects of high-intensity training combined with oral sodium bicarbonate intervention on the aging physiology of healthy subjects through a randomized parallel controlled experimental design. Secondary purpose Evaluate the independent effects of high-intensity training on the aging status of healthy individuals. Exploring the synergistic effect of sodium bicarbonate supplementation on aging after high-intensity training |
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
药物成份或治疗方案详述: |
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Description for medicine or protocol of treatment in detail: |
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
纳入标准: |
1.基础入选条件 人口学指标 年龄:18~60周岁(含边界值) 性别:不限(需记录性别分布,最终入组需满足实验组和对照组性别比1:1) BMI指数:18.5<=BMI<=23.9 kg/m^2(精确至小数点后1位) 生命体征参数 静息血压:收缩压<=130 mmHg且舒张压<=85 mmHg 基础心率:55~100次/分钟(安静状态下) 体温:36℃~37.2℃(腋温检测) 2.健康状况要求 临床检验指标(近一月内报告) 血常规: 血红蛋白:男性>=130 g/L,女性>=120 g/L 白细胞计数:(4~10)×10^9/L 空腹血糖:3.9~6.1 mmol/L 血脂四项: 总胆固醇 < 5.18 mmol/L LDLC < 3.37 mmol/L 3.病史及用药情况 无以下病史记录: 心脑血管疾病(冠心病、卒中病史等) 代谢性疾病(糖尿病、甲状腺功能异常等) 肌肉骨骼系统损伤史(最近五年) 当前未使用激素类药物、抗精神病药物及其他影响运动能力的药物 4.运动适应性评估 心肺功能测试 最大摄氧量(VO?max) >= 对应年龄性别第50百分位数值 运动负荷试验中无ST段异常改变(Bruce方案评估) 体能基线测试 1分钟俯卧撑次数 >= 男性20次/女性12次 坐位体前屈 >= +10 cm (5)其他准入条件 法律及认知要求 持有有效身份证明的完全民事行为能力人; 授权前知情同意流程: 完整阅读知情同意书并自主签署>指定代理人诵读知情同意书并自主签署>指定代理人诵读并签署知情同意书 若存在指定代理人,则需指定代理人一同签署知情同意书,及代理人相关文件。 研究依从性: 承诺可连续参与训练计划(出勤率>=85%) 同意依从研究方的饮食管理(每日>=20小时) |
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Inclusion criteria |
1. Basic selection conditions Demographic indicators Age: 18~60 years old (including boundary value) Gender: unlimited (gender distribution needs to be recorded, and the final enrollment needs to meet the sex ratio of 1:1 between the experimental group and the control group) BMI: 18.5<=BMI<=23.9 kg/m^2 (accurate to 1 decimal place) Vital sign parameters Resting blood pressure: systolic blood pressure < = 130 mmHg and diastolic blood pressure < = 85 mmHg Basal heart rate: 55~100 beats/min (in quiet state) Body temperature: 36°C~37.2°C (axillary temperature detection) 2. Health requirements Clinical test indicators (reported in the past month) complete blood count: Hemoglobin: > = 130 g/L for men and > = 120 g/L for women White blood cell count: (4~10)×10^9/L Fasting blood glucose: 3.9~6.1 mmol/L Four lipids: Total cholesterol < 5.18 mmol/L LDLC < 3.37 mmol/L 3. Medical history and medication No of the following medical history was recorded: Cardiovascular and cerebrovascular diseases (coronary heart disease, stroke history, etc.) Metabolic diseases (diabetes, thyroid dysfunction, etc.) History of musculoskeletal system injury (last five years) No current use of hormonal drugs, antipsychotic drugs, and other drugs that affect exercise capacity 4. Exercise fitness assessment Cardiopulmonary function test Maximum oxygen uptake (VO?max) >= Corresponding to the 50th percentile value of age and sex No abnormal ST segment changes in exercise stress test (assessed by Bruce's protocol) Baseline physical fitness test Number of push-ups in 1 minute > = 20 reps for men / 12 reps for women Anterior flexion of the seated body > = 10 cm (5) Other access conditions Legal and Cognitive Requirements Persons with full capacity for civil conduct who hold valid identity certificates; Pre-Authorization Informed Consent Process: Read the informed consent form completely and sign it independently> designated agent reads the informed consent form and signs it independently> designated agent reads and signs the informed consent form If there is a designated agent, the designated agent is required to sign the informed consent form and the relevant documents of the agent. Study Adherence: Commitment to continuous participation in the training program (attendance >=85%) Agree to comply with the dietary management of the study side (>=20 hours per day) |
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
排除标准: |
1.入组前3个月内参与过任何干预性临床研究(包括药物/器械/生物制剂试验); 2.重大系统性疾病史 (需满足当前仍存在临床意义),详情如下: 循环系统疾病(如冠心病、高血压Ⅱ级以上、严重心律失常) 代谢内分泌疾病(糖尿病、甲状腺功能亢进/减退症等,泌尿系统疾病(慢性肾脏病3期及以上),神经系统疾病(癫痫、卒中后遗症等),免疫系统异常(原发性/获得性免疫缺陷、自身免疫性疾病),其他系统性疾病(血液系统、呼吸系统、精神类疾病等); 3.肾功能限制要求(血清肌酐需采用标准化检测方法) CockcroftGault公式计算肌酐清除率(CrCl)<80mL/min; CrCl = [(140-年龄) × 体重(kg)] / [0.814 × Scr(μmol/L)] 4.临床检查异常, 入选时存在以下任何临床显著异常(研究者判定):体格检查异常体征墩、ECG病理性改变 、实验室检测值超出正常范围20%以上 、超声/放射影像学显著异常 、生命体征持续偏离基线值 ; 5.其他不宜入选情形:经研究团队综合评估存在影响研究完整性或受试者安全的特殊情形 。 |
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Exclusion criteria: |
1. Participated in any interventional clinical study (including drug/device/biologics trial) within 3 months prior to enrollment; 2. History of major systemic disease (subject to clinical significance), details as follows: Circulatory diseases (e.g., coronary heart disease, hypertension over level II, severe arrhythmias) Metabolic endocrine diseases (diabetes, hyperthyroidism/hypothyroidism, etc.), urological diseases (chronic kidney disease stage 3 and above), neurological diseases (epilepsy, stroke sequelae, etc.), immune system abnormalities (primary/acquired immunodeficiency, autoimmune diseases), other systemic diseases (hematological, respiratory, psychiatric diseases, etc.); 3. Requirements for renal function limitation (serum creatinine needs to be tested by standardized testing methods) The CockcroftGault formula calculates creatinine clearance (CrCl) < 80 mL/min; CrCl = [(140-age) × body weight (kg)] / [0.814 × Scr(μmol/L)] 4. Abnormal clinical examination, any of the following clinically significant abnormalities (as judged by the investigator) at the time of enrollment: abnormal signs of physical examination, pathological changes in ECG, laboratory test values exceeding the normal range by more than 20%, significant abnormalities in ultrasound/radiological imaging, and persistent deviation of vital signs from the baseline value; 5. Other circumstances that are not suitable for selection: There are special circumstances that affect the integrity of the study or the safety of subjects as comprehensively assessed by the research team. |
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
研究实施时间: Study execute time: |
从 From 2024-05-10 00:00:00至 To 2026-08-10 00:00:00 |
征募观察对象时间: Recruiting time: |
从 From 2025-06-10 00:00:00 至 To 2025-08-10 00:00:00 |
|
干预措施: Interventions: |
|
|
研究实施地点: Countries of recruitment and research settings: |
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
测量指标: Outcomes: |
|
|
采集人体标本:
Collecting sample(s)
|
|
|
征募研究对象情况: Recruiting status: |
尚未开始 Not yet recruiting |
年龄范围: Participant age: |
|
||||||
|
性别: |
男女均可 |
Gender: |
Both |
||||||
|
随机方法(请说明由何人用什么方法产生随机序列): |
由统计师采用SAS 9.4软件生成分层区组随机序列 每个分层组合单独生成随机序列 区组长度设置为4以保证分配平衡 |
||||||||
|
Randomization Procedure (please state who generates the random number sequence and by what method): |
Generate stratified block random sequences using SAS 9.4 software by statisticians Generate random sequences separately for each hierarchical combination Set the block length to 4 to ensure balanced allocation |
||||||||
|
是否公开试验完成后的统计结果: Calculated Results after the Study Completed public access: |
不公开/Private |
|
盲法: |
对研究参与者设盲 |
|
Blinding: |
Study participants were blinded |
|
是否共享原始数据: IPD sharing |
否No |
|
共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址): |
无 |
|
The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url): |
None |
|
数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC: |
CRF |
|
Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture: |
CRF |
|
数据与安全监察委员会: Data and Safety Monitoring Committee: |
暂未确定/Not yet |